-
公开(公告)号：JP2013048936A
公开(公告)日：2013-03-14
申请号：JP2012267243
申请日：2012-12-06
申请人： Baxter Internatl Inc , バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated , Baxter Healthcare Sa , バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare S.A.
发明人： RHEE WOONZA M , REICH CARY J , OSAWA A EDWARD , VEGA FELIX
CPC分类号： A61K47/42 , A61K9/70 , A61K38/363 , A61K38/4833 , A61K47/34 , A61L24/001 , A61L24/0031 , A61L24/06 , A61L31/044 , A61L31/145 , A61L31/146 , Y10T428/249983 , C08L71/02
摘要： PROBLEM TO BE SOLVED: To provide a rapidly acting dry sealant and methods for use and manufacture.SOLUTION: There are provided compositions, methods, and kits for sealing applications. The compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties. A composition includes a first cross-linkable component, a second cross-linkable component that cross-links with the first cross-linkable component under reaction enabling conditions, and a hydrogel-forming component. The first and second cross-linkable component cross-link to form a porous matrix having interstices, and the hydrogel-forming component is capable of being hydrated to form a hydrogel to fill at least some of the interstices.
摘要翻译： 要解决的问题：提供快速作用的干燥密封剂和使用和制造方法。
解决方案：提供了用于密封应用的组合物，方法和试剂盒。 通过将第一可交联组分与第二可交联组分组合以形成具有间隙的多孔基质并将多孔基质与形成水凝胶的组分相结合以填充至少一些间隙来制备组合物。 组合物表现出最小的溶胀特性。 组合物包括第一可交联组分，在反应条件下与第一可交联组分交联的第二可交联组分和水凝胶形成组分。 第一和第二可交联组分交联以形成具有间隙的多孔基质，并且所述水凝胶形成组分能够被水合以形成水凝胶以填充至少一些间隙。 版权所有（C）2013，JPO＆INPIT
-
公开(公告)号：JP2012126743A
公开(公告)日：2012-07-05
申请号：JP2012073839
申请日：2012-03-28
申请人： Baxter Healthcare Sa , Baxter Internatl Inc , バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated , バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare S.A.
发明人： DONOVAN SHANE , BAKER DONALD A
CPC分类号： A61K38/36 , A61K38/4846
摘要： PROBLEM TO BE SOLVED: To provide a method for treatment of blood coagulation pathologies by pharmaceutical preparations containing Factor IXa.SOLUTION: The invention provides a method of treating bleeding disorders in a subject by administration of a preparation enriched for Factor IXa. The method includes a step of administering a pharmaceutical preparation containing at least 10% Factor IXa (mg/mg total protein). The Factor IXa can be produced by proteolytically activating recombinantly-produced Factor IX. The invention also provides a method for producing Factor IXa from a plasma fraction, which method results in a Factor IXa product containing little or no prekallikrein activity.
摘要翻译： 待解决的问题：提供通过含有因子IXa的药物制剂治疗凝血病理学的方法。 解决方案：本发明提供了通过施用富含因子IXa的制剂来治疗受试者的出血性疾病的方法。 该方法包括施用含有至少10％因子IXa（mg / mg总蛋白）的药物制剂的步骤。 因子IXa可以通过蛋白水解激活重组产生的因子IX产生。 本发明还提供了从血浆级分产生因子IXa的方法，该方法产生含有很少或不具有前激肽释放酶活性的因子IXa产物。 版权所有（C）2012，JPO＆INPIT
-
23.发明专利Method for inactivating microorganism in biological fluid, flow through reactor and method for controlling light sum dose to effectively inactivate microorganism in batch reactor 审中-公开生物流体中的微生物灭活方法，反应器流动方法和控制轻剂量方法有效地使批次反应器中的微生物失活
公开(公告)号：JP2012066103A
公开(公告)日：2012-04-05
申请号：JP2011250848
申请日：2011-11-16
申请人： Baxter Healthcare Sa , Baxter Internatl Inc , バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated , バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare S.A.
发明人： ANDERLE HEINZ , MATTHIESSEN PETER , SCHWARZ HANS-PETER , TURECEK PETER , KREIL THOMAS , BOGGS DANIEL R
CPC分类号： A61L2/10 , A23L3/26 , A23L3/28 , A61L2/0011 , A61L2/28 , G01N21/33 , H05B3/0052
摘要： PROBLEM TO BE SOLVED: To provide a method for effectively inactivating microorganisms included in a biological fluid, especially a non-transparent biological fluid without preferably having an effect on a target bioactive substance.SOLUTION: The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate the microorganisms present in the biological fluid, preferably the non-transparent fluid. Moreover, there is provided a method for inactivating the microorganisms in the biological fluid in a flow-through-reactor. Moreover, the invention provides the useful flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate the microorganisms present in the biological fluid in a batch reactor.
摘要翻译： 要解决的问题：提供一种有效地灭活包括在生物流体中的微生物，特别是非透明生物流体的方法，而不优选对目标生物活性物质具有影响。 解决方案：本发明涉及一种用于确定来自一个或多个光源的有效剂量的单色或多色光以灭活存在于生物流体中的微生物，优选非透明流体的方法。 此外，提供了一种使流过反应器中的生物流体中的微生物灭活的方法。 此外，本发明提供了具有一个或多个恒温光源的有用的流通反应器。 本发明还提供了一种控制从一个或多个光源发射的单色或多色光的光总量的方法，以有效地灭活间歇反应器中存在于生物流体中的微生物。 版权所有（C）2012，JPO＆INPIT
-
24.发明专利Method for treating of hemorrhagic disease by using sulfated polysaccharide 审中-公开通过使用磺化多糖治疗肝硬化疾病的方法
公开(公告)号：JP2012046551A
公开(公告)日：2012-03-08
申请号：JP2011266214
申请日：2011-12-05
申请人： Baxter Healthcare Sa , Baxter Internatl Inc , バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated , バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare S.A.
发明人： JOHNSON KIRK W
IPC分类号： A61K31/737 , A61K31/717 , A61K31/727 , A61K38/36 , A61K38/48 , A61K45/00 , A61K45/06 , A61P7/04 , A61P43/00 , G01N33/86
CPC分类号： A61K31/727 , A61K31/731 , A61K31/737 , A61K38/36 , A61K38/37 , A61K38/4846 , A61K45/06 , Y10S514/834 , A61K2300/00
摘要： PROBLEM TO BE SOLVED: To provide a new healing approach for treatment of hemorrhagic diseases.SOLUTION: Disclosed is a healing approach for treating hemorrhagic diseases by using a non-anticoagulant sulfated polysaccharide (NASP) as a procoagulant. The NASP can be dosed to promote an arrest of hemorrhage as a single agent, in assortative combination, or in combination with another drug (for instance, factor VII, factor VIII, or I X factor). Especially, usage of NASP in treating of the hemorrhagic diseases including a congenital coagulation disorder caused by a blood factor deficiency, an acquired coagulation disorder, and a bleeding status caused by an external injury is explained.
摘要翻译： 要解决的问题：为治疗出血性疾病提供新的治疗方法。 解决方案：公开了通过使用非抗凝血硫酸多糖（NASP）作为促凝血剂来治疗出血性疾病的愈合方法。 NASP可用于促进作为单一药物，分类组合或与另一种药物（例如因子VII，因子VIII或I X因子）联合作为止血药。 特别地，解释了NASP在治疗由血液因子缺乏引起的先天性凝血障碍，获得性凝血障碍和由外部损伤引起的出血状态的出血性疾病的用途。 版权所有（C）2012，JPO＆INPIT
-
公开(公告)号：JP2012020159A
公开(公告)日：2012-02-02
申请号：JP2011207994
申请日：2011-09-22
发明人： GILLESPIE JR JOHN , LABEDZ RALPH H , PLATT MICHAEL KENNETH , SPANG JR RONALD H , BERRILL JAMES FREI , VOGEL MATTHEW STEPHEN , GREANEY MICHELLE KOWALSKI
CPC分类号： A61M5/142 , A61M5/1456 , A61M5/14566 , A61M5/172 , A61M2005/14208 , A61M2005/14573 , A61M2205/21 , A61M2205/6054 , A61M2205/8206 , A61M2205/8237 , A61M2209/086 , G01B7/00 , G01B7/003 , G06T3/60
摘要： PROBLEM TO BE SOLVED: To provide an infusion pump having a new structure.SOLUTION: The infusion pump 10 configured to be powered by either a disposable battery source or a rechargeable battery source includes: a housing 12 having a recess; and a motor which is positioned within the housing 12, is operably connected to an electrical contact disposed in the recess, and powers the pump. The recess receives one of a rechargeable battery unit having an electrical contact that contacts the recess electrical contact, and a disposable battery unit having an electrical contact that contacts the recess electrical contact.
摘要翻译： 要解决的问题：提供具有新结构的输液泵。 解决方案：构造成由一次性电池源或可再充电电池源供电的输液泵10包括：具有凹部的壳体12; 并且位于壳体12内的电动机可操作地连接到设置在凹部中的电触点，并为泵供电。 凹部接收具有与凹部电接触件接触的电接触件的可再充电电池单元中的一个，以及具有接触凹部电接触件的电接触件的一次性电池单元。 版权所有（C）2012，JPO＆INPIT
-
26.发明专利Oligonucleotide-containing microsphere, usage thereof for production of medicament for treatment of type 1 diabetes 有权含有寡核苷酸的微球，用于生产用于治疗1型糖尿病的药物
公开(公告)号：JP2011256204A
公开(公告)日：2011-12-22
申请号：JP2011199945
申请日：2011-09-13
申请人： Baxter Healthcare Sa , Baxter Internatl Inc , Children's Hospital Of Pittsburgh , チルドレンズ ホスピタル オブ ピッツバーグ , バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated , バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare S.A.
发明人： SCOTT TERENCE L , LAFRENIERE DEBORAH , GIANNOUKAKIS NICK , BISKER-LEIB VERED , BROWN LARRY L , MACHEN JENNIFER
IPC分类号： A61K31/711 , A61K9/00 , A61K9/14 , A61K9/16 , A61K9/50 , A61K47/34 , A61K47/48 , A61K48/00 , A61P3/10 , C12N15/09 , C12N15/11 , C12N15/113
CPC分类号： C12N15/1138 , A61K9/0019 , A61K9/1635 , A61K9/1641 , A61K9/1658 , A61K9/19 , C12N15/111 , C12N2310/11 , C12N2310/315 , C12N2320/32
摘要： PROBLEM TO BE SOLVED: To provide delivery of AS (Antisense)-oligonucleotide microspheres to induce dendritic cell tolerance in a non-obese-diabetic (NOD) mouse model.SOLUTION: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in a non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. The process includes using an antisense approach to prevent an autoimmune diabetes condition in an NOD mouse in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
摘要翻译： 要解决的问题：提供AS（反义） - 寡核苷酸微球的输送以在非肥胖 - 糖尿病（NOD）小鼠模型中诱导树突状细胞耐受。 解决方案：AS-寡核苷酸以微球形式递送，以诱导树突细胞耐受，特别是在非肥胖 - 糖尿病（NOD）小鼠模型中。 微球合并反义（AS）寡核苷酸。 该方法包括使用反义方法在体内和原位防止NOD小鼠中的自身免疫性糖尿病状况。 靶向寡核苷酸以结合初级转录物CD40，CD80，CD86及其组合。 版权所有（C）2012，JPO＆INPIT
-
27.发明专利High convection home hemodialysis/hemofiltration and sorbent system 有权高对流主页肝细胞分析/ HEMOFILTRATION和SORBENT系统
公开(公告)号：JP2011206597A
公开(公告)日：2011-10-20
申请号：JP2011163710
申请日：2011-07-26
申请人： Baxter Healthcare Sa , Baxter Internatl Inc , バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated , バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare S.A.
发明人： KELLY THOMAS D , CHILDERS ROBERT W , BUSBY DON , ROGER RODOLFO , EL SAYYID WALEED MUTASEM , DIN SHAHID Q
CPC分类号： A61M1/3621 , A61M1/1006 , A61M1/101 , A61M1/1012 , A61M1/1037 , A61M1/1039 , A61M1/1062 , A61M1/1081 , A61M1/1086 , A61M1/16 , A61M1/1601 , A61M1/1607 , A61M1/1613 , A61M1/1621 , A61M1/1629 , A61M1/1633 , A61M1/1635 , A61M1/1656 , A61M1/166 , A61M1/1668 , A61M1/167 , A61M1/1672 , A61M1/1696 , A61M1/267 , A61M1/288 , A61M1/341 , A61M1/3417 , A61M1/342 , A61M1/3427 , A61M1/3431 , A61M1/3434 , A61M1/3437 , A61M1/3444 , A61M1/3451 , A61M1/3458 , A61M1/3465 , A61M1/3468 , A61M1/3472 , A61M1/3486 , A61M1/3624 , A61M1/3626 , A61M1/3627 , A61M1/3643 , A61M1/3644 , A61M1/3646 , A61M1/3647 , A61M1/3649 , A61M1/365 , A61M1/3652 , A61M1/3656 , A61M2202/0413 , A61M2205/12 , A61M2205/13 , A61M2205/15 , A61M2205/18 , A61M2205/276 , A61M2205/3317 , A61M2205/3324 , A61M2205/3327 , A61M2205/3331 , A61M2205/3334 , A61M2205/3337 , A61M2205/3344 , A61M2205/3368 , A61M2205/3379 , A61M2205/3393 , A61M2205/3553 , A61M2205/3561 , A61M2205/3584 , A61M2205/502 , A61M2205/505 , A61M2205/52 , A61M2205/75
摘要： PROBLEM TO BE SOLVED: To provide a system, method and apparatus for performing a renal replacement therapy.SOLUTION: Two small high flux dialyzers (20, 30) are connected in series. A restriction means (40) is placed between the two dialyzers in the dialysate flow path (962). The restriction means is variable and adjustable. The restriction means builds a positive pressure in the venous dialyzer, causing a high degree of intentional backfiltration. That backfiltration causes a significant flow of dialysate through the high flux venous membrane to directly flow into the patient's blood. The backfiltered solution is subsequently ultrafiltered from the patient from the arterial dialyzer. The diffusion of dialysate into the venous filter and removal of dialysate from the arterial dialyzer causes a convective transport of toxins from the patient. Additionally, the dialysate that does not diffuse directly into the patient but flows across the membranes of both dialyzers provides a diffusive clearance of waste products.
摘要翻译： 要解决的问题：提供用于进行肾脏替代疗法的系统，方法和装置。解决方案：两个小型高通量透析器（20,30）串联连接。 限制装置（40）被放置在透析液流动路径（962）中的两个透析器之间。 限制装置是可变的和可调节的。 限制意味着在静脉透析器中建立正压力，导致高度有意的反渗透。 该回流导致透析液通过高通量静脉膜的显着流动直接流入患者的血液。 反渗滤液随后从动脉透析器从患者超滤。 透析液扩散到静脉过滤器中，从动脉透析器中除去透析液会导致患者的毒素对流运输。 另外，不直接扩散到患者体内但流过透析器的膜的透析液提供废物的扩散清除。
-
28.发明专利
公开(公告)号：JP2011189196A
公开(公告)日：2011-09-29
申请号：JP2011147666
申请日：2011-07-01
申请人： Baxter Healthcare Sa , Baxter Internatl Inc , バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated , バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare S.A.
发明人： LI PATRICK , BIEWER JOHN , CHILDERS ROBERT , FOOHEY MARK W , GILBERT RICHARD , KOPYCHEV ANDREY , MURPHEY RANDY , ORAND AUSTIN , REITZ DOUGLAS , ROGER ROGER , STECK JOHN
CPC分类号： A61M5/162 , A61M1/28 , A61M1/284 , A61M5/16813 , A61M39/18 , A61M2205/12 , A61M2205/58 , A61M2205/6054 , A61M2205/6072 , Y10T29/49826 , Y10T137/6116
摘要： PROBLEM TO BE SOLVED: To provide a system and method for dialysis medical fluid therapy taking a cassette as a base material, and provide a fluid dispensing machine using a peristaltic pump and a diaphragm pump. SOLUTION: The fluid dispensing machine, such as a peritoneal dialysis or hemodialysis machine, includes a dispenser or cassette (3) that pumps a medical fluid for dialysis or other treatment for patients. The machine includes and uses an autoconnect device (5) for connecting containers of liquid, such as bags of dialysis fluid or medication fluids, to the machine, while maintaining the sterility of the connection. The autoconnect device removes the cap from the fluid bag tubing and pierces the sealing membrane on the tubing. This makes it easier for patients to receive treatment, especially home treatment. Other embodiments are useful for dispensing other liquids from other types of dispensing or pumping machines. COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译： 要解决的问题：提供一种以盒式磁带作为基材的透析医用液体治疗系统和方法，并提供使用蠕动泵和隔膜泵的流体分配机。 流体分配机器，例如腹膜透析或血液透析机，包括一个分配器或盒式磁带（3），用于泵送用于患者的透析或其它治疗的医用流体。 该机器包括并使用自动连接装置（5），用于将诸如透析液或药液的液体容器连接到机器，同时保持连接的不连续性。 自动连接装置从流体袋管道中取出盖子并刺穿管道上的密封膜。 这使患者更容易接受治疗，特别是家庭治疗。 其他实施例可用于从其他类型的分配或泵送机器分配其它液体。 版权所有（C）2011，JPO＆INPIT
-
公开(公告)号：JP2011041580A
公开(公告)日：2011-03-03
申请号：JP2010265835
申请日：2010-11-29
申请人： Baxter Healthcare Sa , Baxter Internatl Inc , バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated , バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare S.A.
IPC分类号： C12N1/00 , A61K39/12 , A61K39/145 , A61K39/275 , A61K39/285 , A61P37/02 , C12N5/00 , C12N5/02 , C12N5/06 , C12N5/10 , C12N7/00
CPC分类号： C12N5/005 , A61K39/12 , A61K39/145 , A61K39/275 , A61K39/285 , C12N5/0043 , C12N7/00 , C12N2500/74 , C12N2500/76 , C12N2710/24134 , C12N2760/16134 , C12N2770/36134
摘要： PROBLEM TO BE SOLVED: To provide animal protein-free cell culture media.
SOLUTION: The animal protein-free cell culture media comprises a combination of non-animal derived peptides derived from soy hydrolysate and yeast hydrolysate. The invention also provides an animal protein-free culture process, wherein cells are cultivated, propagated and passaged without animal-derived components. This process is useful for cultivating cells, such as recombinant cells or cells infected with a virus, and for production biological products by cell culture processes under conditions devoid of animal protein components.
COPYRIGHT: (C)2011,JPO&INPIT摘要翻译： 要解决的问题：提供无动物蛋白的细胞培养基。 解决方案：无动物蛋白质的细胞培养基包含衍生自大豆水解产物和酵母水解产物的非动物衍生肽的组合。 本发明还提供了一种无动物蛋白质的培养方法，其中培养，繁殖和传代细胞而没有动物衍生的成分。 该方法可用于培养细胞，例如重组细胞或感染病毒的细胞，以及在没有动物蛋白质组分的条件下通过细胞培养方法生产生物产物。 版权所有（C）2011，JPO＆INPIT
-
30.发明专利Vitamin k epoxide recycling polypeptide vkorc1, and therapeutic target of coumarin and its derivative 审中-公开维生素K环氧化物回收多肽VKORC1，以及COUMARIN及其衍生物的治疗目标
公开(公告)号：JP2011013231A
公开(公告)日：2011-01-20
申请号：JP2010224376
申请日：2010-10-01
申请人： Baxter Healthcare Sa , Baxter Internatl Inc , バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated , バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare S.A.
发明人： OLDENBURG JOHANNES , MUELLER-REIBLE CLEMENS R , FREGIN ANDREAS , STROM TIM-MATHHIAS , ROST SIMONE
IPC分类号： G01N33/50 , A01N43/16 , A61K38/44 , C07H21/04 , C07K14/435 , C12N5/06 , C12N9/02 , C12N9/04 , C12Q1/68 , G01N33/15
CPC分类号： C12N9/0006 , A01K67/0276 , A01K2267/01 , C07K16/40 , C12N15/1137 , C12N15/115 , C12N15/62 , C12N2310/11 , C12N2310/14 , C12N2310/16 , C12N2310/531 , C12Q1/26 , C12Q1/6876 , C12Q1/6883 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Y101/04001
摘要： PROBLEM TO BE SOLVED: To provide a novel polypeptide vitamin K epoxide reductase complex subunit 1 (VKORC1) as a target for coumarin and its derivatives.SOLUTION: The invention relates to a novel polypeptide vitamin K epoxide reductase complex subunit 1 (VKORC1) as a target for coumarin and its derivatives. The invention further provides a method for identifying coumarin derivatives, and also claims VKORC1 polypeptides and VKORC1 nucleic acids containing a sequence abnormality associated with a VKORC1 associated deficiency such as warfarin resistance. The VKORC1 polypeptides and VKORC1 nucleic acids can be used for diagnosing these deficiencies. Moreover, the invention relates to methods for identifying coumarin derivatives usable in pest control of rodents.
摘要翻译： 要解决的问题：提供新颖的多肽维生素K环氧化物还原酶复合物亚单位1（VKORC1）作为香豆素及其衍生物的靶标。解决方案：本发明涉及一种新型多肽维生素K环氧化物还原酶复合亚单位1（VKORC1）作为 香豆素及其衍生物的目标。 本发明还提供了一种鉴定香豆素衍生物的方法，并且还要求含有与VKORC1相关缺乏如华法林抗性相关的序列异常的VKORC1多肽和VKORC1核酸。 VKORC1多肽和VKORC1核酸可用于诊断这些缺陷。 此外，本发明涉及鉴定可用于啮齿动物害虫控制的香豆素衍生物的方法。
-
-
-
-
-
-
-
-
-
搜索结果
269 条记录 (耗时 0.052 秒)
